Loading...
XWARCLN
Market cap329mUSD
Dec 20, Last price  
25.00PLN
1D
-1.38%
1Q
-9.75%
IPO
-20.84%
Name

Celon Pharma SA

Chart & Performance

D1W1MN
XWAR:CLN chart
P/E
—
P/S
8.19
EPS
—
Div Yield, %
0.34%
Shrs. gr., 5y
2.56%
Rev. gr., 5y
5.59%
Revenues
164m
+1.53%
40,109,16171,640,12598,099,063107,540,270128,777,939107,120,079125,244,805102,247,205139,270,000169,559,000161,915,000164,394,000
Net income
-28m
L-28.40%
1,333,50817,957,73252,207,12037,180,21537,807,41925,615,33229,697,10411,934,95821,495,000-11,607,000-39,277,000-28,124,000
CFO
-8m
L+76.86%
12,866,6868,450,09924,358,09952,368,29120,645,69925,302,74528,240,315070,904,00043,952,000-4,701,000-8,314,000
Dividend
Jun 27, 20240.08 PLN/sh
Earnings
Apr 23, 2025

Profile

Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.
URL
https://celonpharma.com/
IPO date
Dec 01, 2016
Employees
521
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
164,394
1.53%
161,915
-4.51%
169,559
21.75%
Cost of revenue
67,499
129,461
148,153
Unusual Expense (Income)
NOPBT
96,895
32,454
21,406
NOPBT Margin
58.94%
20.04%
12.62%
Operating Taxes
8,156
2,831
(3,480)
Tax Rate
8.42%
8.72%
NOPAT
88,739
29,623
24,886
Net income
(28,124)
-28.40%
(39,277)
238.39%
(11,607)
-154.00%
Dividends
(4,595)
(14,800)
(3,150)
Dividend yield
0.58%
2.07%
0.20%
Proceeds from repurchase of equity
2
4
216,000
BB yield
0.00%
0.00%
-13.96%
Debt
Debt current
19,880
19,434
6,563
Long-term debt
(4,337)
34,210
23,271
Deferred revenue
22,884
29,851
Other long-term liabilities
5,810
4,146
22,526
Net debt
(28,231)
(42,503)
(156,083)
Cash flow
Cash from operating activities
(8,314)
(4,701)
43,952
CAPEX
(32,813)
(33,906)
(41,352)
Cash from investing activities
(21,640)
(31,472)
(121,048)
Cash from financing activities
(20,589)
(28,721)
180,914
FCF
52,985
52,037
43,290
Balance
Cash
114,543
164,624
227,551
Long term investments
(70,769)
(68,477)
(41,634)
Excess cash
35,554
88,051
177,439
Stockholders' equity
(97,676)
479,646
554,002
Invested Capital
597,516
422,563
443,857
ROIC
17.40%
6.84%
4.86%
ROCE
19.27%
6.34%
3.41%
EV
Common stock shares outstanding
51,056
51,024
46,677
Price
15.46
10.27%
14.02
-57.71%
33.15
-18.25%
Market cap
789,333
10.34%
715,362
-53.77%
1,547,333
-15.20%
EV
761,102
672,859
1,391,250
EBITDA
146,911
76,549
62,748
EV/EBITDA
5.18
8.79
22.17
Interest
2,662
1,671
1,553
Interest/NOPBT
2.75%
5.15%
7.25%